GSK (LON:GSK) Stock Rating Reaffirmed as “Hold” by Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating restated by investment analysts at Deutsche Bank Aktiengesellschaft in a report released on Tuesday, Digital Look reports. They presently have a GBX 2,000 target price on the stock. Deutsche Bank Aktiengesellschaft’s target price would indicate a potential upside of 9.02% from the company’s current price.

Other equities research analysts have also recently issued research reports about the stock. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research report on Wednesday, July 29th. Royal Bank Of Canada restated a “sector perform” rating and issued a GBX 1,975 price objective on shares of GSK in a report on Tuesday, September 8th. Finally, Berenberg Bank raised their price objective on shares of GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a research note on Tuesday, September 15th. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of GBX 2,064.38.

GSK Trading Down 1.2%

Shares of LON GSK traded down GBX 21.50 during midday trading on Tuesday, hitting GBX 1,834.50. The stock had a trading volume of 118,997,156 shares, compared to its average volume of 13,441,223. The firm has a market cap of £73.51 billion, a P/E ratio of 15.57, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. GSK has a fifty-two week low of GBX 1,590.50 and a fifty-two week high of GBX 2,282. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73. The company’s 50-day simple moving average is GBX 1,886.30 and its 200 day simple moving average is GBX 1,945.14.

GSK (LON:GSK) last issued its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. Research analysts anticipate that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling

In other news, insider Anne Beal bought 637 shares of the stock in a transaction on Friday, September 18th. The stock was purchased at an average price of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds bought 1,500 shares of the business’s stock in a transaction on Friday, September 18th. The stock was purchased at an average price of GBX 1,881 per share, for a total transaction of £28,215. In the last 90 days, insiders have purchased 2,144 shares of company stock valued at $6,009,566. Corporate insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.